am833 semaglutide Cagrilintide–semaglutide (CagriSema) versus or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study Prescribed online with board PDF) Preclinical Weight Loss Efficacy

Furthermore, some governments in Europe have explicitly asked clinicians not to prescribe GLP-1s for obesity and instead reserve them for people with Type 2 diabetes

Therefore, MedTech companies should focus on the five essential steps mentioned before to prepare for success in a healthcare landscape directly shaped by GLP-1 advancements

Dr Max Taquet, Clinical Lecturer at the University of Oxford and senior author of the study, added: Our study is observational and these results should therefore be replicated in a randomised controlled trial to confirm and extend our findings. Nevertheless, they are good news for patients with psychiatric disorders, who are at an increased risk of diabetes. While semaglutide is also used in people with obesity, with most diabetes patients with type 2 diabetes also presenting being overweight or obese, the findings from this study cannot be applied to people who do not have diabetes.

For newer medications like semaglutide and tirzepatide, that average was higher, approximately 0.8 kg per month

doi: 10.1210/jc.2018-01713 27 FederigeMAFRomaldiniJHMiklosAKoikeMKTakeiKPortesES